Phase II FRACTION-RCC Adaptive Design Trial: Nivolumab + Ipilimumab in Advanced RCC Progressing After Checkpoint Inhibitor Therapy

May 29-31, 2020; Online at meetings.asco.org/am
A subset of patients with advanced RCC previously treated with checkpoint inhibitors responded to subsequent treatment with nivolumab + ipilimumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 246 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Downloadable slideset on the assessment of EGFR mutation and MET amplifications status in NSCLC, from Clinical Care Options (CCO)

Alexander Spira, MD, PhD, FACP Released: November 22, 2021

Downloadable slideset on the treatment of NSCLC harboring Exon 20 insertion mutations, from Clinical Care Options (CCO)

Enriqueta Felip, MD Released: November 22, 2021

Download this brief slideset on resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Helena A. Yu, MD Released: November 19, 2021

Concise interactive module featuring Helena A. Yu, MD, on resistance to EGFR TKI therapy in lung cancer, from Clinical Care Options (CCO)

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 19, 2021 Expired: November 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue